| The global biopharmaceutical industry
today faces an array of daunting challenges:
intense pressure to bring innovative
compounds to market more quickly; rapidly
rising development costs; and growing
demands from regulatory and political
bodies to increase drug safety and reduce
prices. Faced with this difficult marketplace
environment, pharmaceutical companies
must find new ways to improve productivity
and reduce costs throughout the clinical
development process if they are to overcome
these challenges in the years ahead.
The second generation of eClinical
technologies – sometimes referred to a
eClinical 2.0 – holds the potential to
help trial sponsors improve development
decision-making, reduce time to market
and enhance patient safety by significantly
improving data access and integration for
every aspect of drug development. Yet the
pharmaceutical industry’s progress in
adopting these new technologies continues
to lag behind that of many other businesses. |
